# Pizarra — PT-pseudo_0de7e606ca70 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_0de7e606ca70
Task: 1

Encounter: Urology - outpatient on 15 Jan 2025.
Referrer: Dr. N. Kuiper (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 9.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.409 ng/mL²
  - PSA velocity: 1.24 ng/mL/yr
  - Prior PSA: 7.8 ng/mL
  - Prostate volume: 22.03 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.886139 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: valsartan, lisinopril
  - Allergies: NKA
  - Additional notes: PSA 9 ng/mL. PI-RADS 5. PSAD 0.41. Prostate volume 22 mL. csPCa 0.89.

Vitals: weight 76 kg, height 183 cm, BMI 22.7, BP 138/91 mmHg, HR 78 bpm. Smoking: Ex-smoker (27 pack-yr, quit 2017).

Chief complaint: Clinical attention directed toward steadily climbing PSA values alongside newly acquired mpMRI results.

History: Primary care surveillance has tracked his PSA trajectory for approximately two years. He is a sixty-five-year-old retired truck driver, never married, yet residing with his partner. Daily habits feature a twenty-minute walking regimen and a weekly alcohol intake capped at four units. Chronic hypertension remains stable on valsartan and lisinopril. He also carries a smoking background of 27 pack-years, though cessation occurred in 2017. Lower urinary tract complaints are minimal, scoring a 7 on the IPSS questionnaire, and he has never experienced urinary retention or visible blood in the urine. Outside of urological care, he recently completed a standard hearing evaluation and consulted a pain specialist regarding persistent right shoulder aches. Administrative correspondence and paperwork are handled by his grown daughter, acting with explicit permission.

Physical examination: DRE: A normal prostate presents with symmetrically smooth contours and uniform consistency, devoid of discrete masses or lateral asymmetry. Systemic evaluation shows stable vitals: a blood pressure of 138/91 mmHg and a pulse rate of 78 bpm. Comprehensive review of systems and vital parameters indicates no peripheral adenopathy or skeletal tenderness.

Patient info: retired truck driver; Never married; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 4 units / week; exercise Walking 20 min/day; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Audiology — hearing test; Pain clinic — chronic shoulder pain.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.88 +/- 0.11   (95% CI 0.59-1.00)

Where the uncertainty comes from:
  - aleatoric  dA = 0.10  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.05  (few labelled cases resemble this one)
  - 8.3 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'firm': A +/- 1.96*dA does not cross the 0.5 threshold. On the 91 labelled cases this tier was never wrong, but it only covered 17 of them, so the 95% CI on that accuracy still reaches down to ~0.75. Treat it as a strong prior that should only be overturned by explicit contradicting evidence.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=0.0, psa=9.0, age=65.0, psad=0.409, dre_ord=0.0, vol=22.03, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only used the visible panel data (PI-RADS=5.0, PSA=9.0, csPCa probability=0.886139, DRE=Normal) and could not account for the PSA velocity (1.24 ng/mL/yr), the PSA density (0.409 ng/mL²), or the specific context of the guideline criteria regarding PSA density thresholds.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy based on a high probability, but the guideline criterion is conditional on PSA density and the specific PI-RADS score relative to the PSA-D risk matrix. The prior's high probability might be misleading if the patient falls into a low-risk category according to the guideline's risk-adapted matrix, which the prior did not evaluate.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
laboratory panel - to check if PSA density is below the 0.15 ng/mL/cc threshold mentioned in the guideline.
previous GP / urology consultation notes - to assess if the patient has any history that might modify the interpretation of the clinical suspicion.
laboratory panel - to confirm the PSA density value used in the guideline risk stratification.

GUIDELINE ANCHOR
The guideline states that biopsy is indicated when the mpMRI shows a PI-RADS 3 or higher lesion, but it also provides risk-adapted matrices using PSA density to guide the decision.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_0de7e606ca70", "radiology_report": "Subject: Prostate mpMRI / Facility: Catharina Ziekenhuis, Eindhoven / Date: 12 January 2025\n\nClinical indication: Assessment of a PSA value of 9.0 alongside clinical concerns for malignancy.\n\nFINDINGS:\nProstate volume registers at 22.03 mL. T2 sequences highlight a discrete hypointense focus in the right peripheral zone, spanning the base to mid gland, with a maximum diameter near 14 mm. Diffusion-weighted imaging shows marked restriction, mirrored by a corresponding drop on the ADC map. Contrast kinetics demonstrate prompt, pronounced focal uptake against background tissue. The capsule remains intact without seminal vesicle involvement, and pelvic nodes appear normal.\n\nIMPRESSION:\nPI-RADS 5 lesion located in the right peripheral zone.\nProstate volume 22.03 mL, PSA density 0.409 ng/mL/mL.\ncsPCa predicted probability 0.886139."}
get_psa_trend
{"case_id": "PT-pseudo_0de7e606ca70", "psa_trend": [{"date": "Aug 2023", "val": 3.3}, {"date": "Feb 2024", "val": 4.6}, {"date": "Jul 2024", "val": 6.4}, {"date": "Jan 2025", "val": 9.0}]}
get_previous_notes
{"case_id": "PT-pseudo_0de7e606ca70", "previous_notes": [{"date": "20 May 2024", "author": "Dr. N. Kuiper (GP)", "text": "Subsequent clinic visit focused on ongoing PSA elevation. A February 2024 draw showed a level of 7.6 ng/mL, continuing a consistent climb from earlier baselines. This trajectory prompted transfer to urology for specialized evaluation and further imaging. Standard laboratory panels fell within expected ranges for his demographic."}, {"date": "25 Jul 2023", "author": "Dr. N. Kuiper (GP)", "text": "Cardiovascular assessment paired with prostate cancer screening metrics. An initial PSA reading of 6.2 ng/mL triggered a confirmatory August draw, which mirrored that elevation. No acute urological complaints were noted during this encounter."}]}
get_lab_results
{"case_id": "PT-pseudo_0de7e606ca70", "laboratory_results": [{"name": "PSA", "val": "9.0 ng/mL", "date": "20 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "2.18 ng/mL", "date": "20 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "24%", "date": "20 Dec 2024", "flag": ""}]}

NOT RETRIEVED
get_family_history
The family history of prostate cancer was not retrieved because the tool was not called.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 5 lesion located in the right peripheral zone with a maximum diameter near 14 mm.
- PSA trend: Rapid rise from 3.3 ng/mL (Aug 2023) to 9.0 ng/mL (Jan 2025), with a velocity of 1.24 ng/mL/yr.

AGAINST sampling this patient now:
- DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).

WHERE THIS LEANS
The combined evidence strongly supports immediate biopsy due to the high-risk PI-RADS 5 finding and the significant, rapid rise in PSA. This confirms the statistical prior but is strongly supported by the imaging findings.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the high-risk PI-RADS 5 finding, which is the primary driver for sampling in this biopsy-naive patient. This decision aligns with the EXPERT-PROTOCOL criterion, which mandates biopsy for PI-RADS 3 or higher lesions. The evidence report confirmed a PI-RADS 5 lesion with a maximum diameter near 14 mm, and the PSA trend showed a rapid rise to 9.0 ng/mL, confirming the clinical suspicion.

Variables that carried weight: age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
